PreoperativeModified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A 021101

MatthewH. G. Katz, MD; Qian Shi, PhD; Syed A. Ahmad, MD; JosephM. Herman, MD; Robert deW. Marsh, MD; Eric Collisson, MD; Lawrence Schwartz, MD;Wendy Frankel, MD; Robert Martin, MD;William Conway, MD; Mark Truty, MD; Hedy Kindler, MD; AndrewM. Lowy, MD; Tanios Bekaii-Saab, MD; Philip Philip, MD, PhD; Mark Talamonti, MD; Dana Cardin, MD; Noelle LoConte, MD; Perry Shen, MD; John P. Hoffman, MD; Alan P. Venook, MD

[1]  Laura H. Tang,et al.  FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma , 2015, Annals of Surgical Oncology.

[2]  B. Erickson,et al.  Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? , 2014, The oncologist.

[3]  Jeffrey E. Lee,et al.  Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer , 2014, Journal of Gastrointestinal Surgery.

[4]  S. Maithel,et al.  Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma , 2013, Pancreas.

[5]  A. Krasinskas,et al.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer , 2013, Journal of surgical oncology.

[6]  Douglas B. Evans,et al.  Rational Study Endpoint(s) for Preoperative Trials in Pancreatic Cancer: Pathologic Response Rate, Margin Negative Resection, Overall Survival or ‘All of the Above’? , 2013, Annals of Surgical Oncology.

[7]  S. Yamada,et al.  Aggressive Surgery for Borderline Resectable Pancreatic Cancer: Evaluation of National Comprehensive Cancer Network Guidelines , 2013, Pancreas.

[8]  M. Pichler,et al.  Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma , 2013, Acta oncologica.

[9]  J. Berlin,et al.  Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design , 2013, Annals of Surgical Oncology.

[10]  Jeffrey E. Lee,et al.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.

[11]  Jeffrey E. Lee,et al.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma , 2012, Cancer.

[12]  S. Yamada,et al.  Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer , 2012, Annals of surgery.

[13]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here? , 2011, Annals of Surgical Oncology.

[14]  R. Abrams,et al.  Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial , 2011, Annals of Surgical Oncology.

[15]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[16]  P. Catalano,et al.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma , 2010, Journal of surgical oncology.

[17]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[18]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[20]  R. Abrams,et al.  Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[21]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[22]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[23]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  P. Mishra,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2015, Annals of surgery.

[26]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[27]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .